TAMPA, Fla. & MINNEAPOLIS--(BUSINESS WIRE)--Biovest International, Inc. (OTCQB:BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB:ABPI), today reported that its correspondence to the Editor was published in the November 2011 issue of the Journal of Clinical Oncology (JCO), defining the role of BiovaxID® as a safe and effective personalized cancer vaccine for the treatment of certain B-cell subtypes of non-Hodgkin’s lymphoma. This letter, authored by Biovest along with leading clinical oncologists from the MD Anderson Cancer Center and the Abramson Cancer Center at the University of Pennsylvania, explains that BiovaxID is a non-immunosuppressive consolidation therapy and highlights the urgent and unmet need for an autologous active immunotherapy for the treatment of follicular lymphoma.
